SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma
| العنوان: | SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma |
|---|---|
| المؤلفون: | Adalbert Krawczyk, Hannes Klump, Marianne Breyer, Veronika Lenz, Laura Thümmler, Lukas van de Sand, Peter A. Horn, Sebastian Dolff, Monika Lindemann, Leonie Schipper, Oliver Witzke, Margarethe Konik, Dietmar Knop, Maximillian Platte, Hana Rohn, Christian Temme, Sina Schwarzkopf, Ulf Dittmer, Maren Bormann |
| المصدر: | Journal of Medical Virology |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cellular immunity, Enzyme-Linked Immunospot Assay, medicine.medical_treatment, Medizin, Antibodies, Viral, Immunoglobulin G, 0302 clinical medicine, 030212 general & internal medicine, Kidney transplantation, Research Articles, Aged, 80 and over, Immunity, Cellular, hemodialysis, biology, ELISPOT, Middle Aged, Infectious Diseases, C-Reactive Protein, Spike Glycoprotein, Coronavirus, convalescent plasma, 030211 gastroenterology & hepatology, Female, Hemodialysis, Antibody, Viral load, Research Article, ELISpot, kidney transplantation, cellular immunity, Antiviral Agents, 03 medical and health sciences, Renal Dialysis, COVID‐19, Virology, medicine, Humans, COVID-19 Serotherapy, Aged, business.industry, SARS-CoV-2, Immunization, Passive, COVID-19, medicine.disease, Antibodies, Neutralizing, Immunity, Humoral, COVID-19 Drug Treatment, Immunology, biology.protein, business, Kidney disease |
| الوصف: | When patients with chronic kidney disease are infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) they can face two specific problems: virus‐specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten recovery, is contraindicated. Antiviral treatment with convalescent plasma (CP) could be an alternative treatment option. In this case report, we present two kidney transplant recipients and two hemodialysis patients who were infected with SARS‐CoV‐2 and received CP. Antibodies against the receptor‐binding domain in the S1 subunit of the SARS‐CoV‐2 spike protein were determined sequentially by immunoglobulin G (IgG) enzyme‐linked immunosorbent assay (ELISA) and neutralization assay and specific cellular responses by interferon‐gamma ELISpot. Before treatment, in both kidney transplant recipients and one hemodialysis patient antibodies were undetectable by ELISA (ratio Highlights After treatment with convalescent plasma we observed an increase of specific humoral and cellular immunity in two kidney transplant recipients and two haemodialysis patients with SARS‐CoV‐2 infection.However, the success of convalescent plasma therapy was only be temporary in one transplant recipient.Short‐term monitoring of viral load and antiviral immunity appears as mandatory for this patient group. |
| تدمد: | 1096-9071 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6b41e46a5278b210c9b50b749d1f671Test https://pubmed.ncbi.nlm.nih.gov/33527424Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c6b41e46a5278b210c9b50b749d1f671 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10969071 |
|---|